

Niamh M O'boyle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/315976/publications.pdf>

Version: 2024-02-01

33
papers

1,086
citations

430754

18
h-index

395590

33
g-index

35
all docs

35
docs citations

35
times ranked

1312
citing authors

#	ARTICLE	IF	CITATIONS
1	Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review. <i>Pharmaceuticals</i> , 2020, 13, 8.	1.7	187
2	Synthesis and Evaluation of Azetidinone Analogues of Combretastatin A-4 as Tubulin Targeting Agents. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 8569-8584.	2.9	111
3	Skin lipids in health and disease: A review. <i>Chemistry and Physics of Lipids</i> , 2021, 236, 105055.	1.5	72
4	Synthesis, evaluation and structural studies of antiproliferative tubulin-targeting azetidin-2-ones. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 2306-2325.	1.4	62
5	Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 90-113.	2.9	57
6	$\hat{\text{I}}^2$ -Lactam Estrogen Receptor Antagonists and a Dual-Targeting Estrogen Receptor/Tubulin Ligand. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9370-9382.	2.9	45
7	The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells. <i>Biochemical Pharmacology</i> , 2012, 84, 612-624.	2.0	44
8	Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 4595-4607.	2.6	41
9	Piperlongumine (piplartine) and analogues: Antiproliferative microtubule-destabilising agents. <i>European Journal of Medicinal Chemistry</i> , 2017, 125, 453-463.	2.6	36
10	$\hat{\text{I}}^2$ -Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2017, 130, 261-285.	2.6	35
11	Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ER $\hat{\text{I}}^{\pm}$ and ER $\hat{\text{I}}^2$ Activity. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 514-534.	2.9	35
12	Special Issue "Anticancer Drugs". <i>Pharmaceuticals</i> , 2019, 12, 134.	1.7	33
13	The Vascular Targeting Agent Combretastatin-A4 and a Novel <i>cis</i> -Restricted $\hat{\text{I}}^2$ -Lactam Analogue, CA-432, Induce Apoptosis in Human Chronic Myeloid Leukemia Cells and Ex Vivo Patient Samples Including Those Displaying Multidrug Resistance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 302-313.	1.3	26
14	Analogues of the Epoxy Resin Monomer Diglycidyl Ether of Bisphenol F: Effects on Contact Allergenic Potency and Cytotoxicity. <i>Chemical Research in Toxicology</i> , 2012, 25, 2469-2478.	1.7	25
15	$\hat{\text{I}}^2$ -Lactams with antiproliferative and antiapoptotic activity in breast and chemoresistant colon cancer cells. <i>European Journal of Medicinal Chemistry</i> , 2020, 189, 112050.	2.6	25
16	Synthesis and biochemical activities of antiproliferative amino acid and phosphate derivatives of microtubule-disrupting $\hat{\text{I}}^2$ -lactam combretastatins. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 705-721.	2.6	23
17	Combretazet-3 a novel synthetic <i>cis</i> -stable combretastatin A-4- azetidinone hybrid with enhanced stability and therapeutic efficacy in colon cancer. <i>Oncology Reports</i> , 2013, 29, 2451-2458.	1.2	22
18	Novel <i>cis</i> -restricted $\hat{\text{I}}^2$ -lactam combretastatin A-4 analogues display anti-vascular and anti-metastatic properties in vitro. <i>Oncology Reports</i> , 2013, 29, 585-594.	1.2	19

#	ARTICLE	IF	CITATIONS
19	Lead identification of β -lactam and related imine inhibitors of the molecular chaperone heat shock protein 90. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6055-6068.	1.4	18
20	Synthesis and evaluation of antiproliferative microtubule-destabilising combretastatin A-4 piperazine conjugates. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 6184-6200.	1.5	15
21	Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2010, 25, 180-194.	2.5	13
22	Combretastatin (CA)-4 and its novel analogue CA-432 impair T-cell migration through the Rho/ROCK signalling pathway. <i>Biochemical Pharmacology</i> , 2014, 92, 544-557.	2.0	13
23	Assessment of cross-reactivity of new less sensitizing epoxy resin monomers in epoxy resin allergic individuals. <i>Contact Dermatitis</i> , 2016, 75, 144-150.	0.8	13
24	Epoxy Resin Monomers with Reduced Skin Sensitizing Potency. <i>Chemical Research in Toxicology</i> , 2014, 27, 1002-1010.	1.7	12
25	Potent Quinoline-Containing Combretastatin A-4 Analogues: Design, Synthesis, Antiproliferative, and Anti-Tubulin Activity. <i>Pharmaceuticals</i> , 2020, 13, 393.	1.7	12
26	3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells. <i>Pharmaceuticals</i> , 2019, 12, 56.	1.7	10
27	Virtual Screening™ Layered Virtual Screening Tool for the Identification of Novel Estrogen Receptor Alpha Modulators. <i>Molecular Informatics</i> , 2010, 29, 421-430.	1.4	7
28	Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4. <i>Pharmaceuticals</i> , 2021, 14, 1119.	1.7	7
29	Nature-derived epoxy resins: Synthesis, allergenicity, and thermosetting properties of pinoresinol diglycidyl ether. <i>Toxicology and Industrial Health</i> , 2022, 38, 259-269.	0.6	7
30	Synthesis and Biological Evaluation of 1-(Diarylmethyl)-1H-1,2,4-triazoles and 1-(Diarylmethyl)-1H-imidazoles as a Novel Class of Anti-Mitotic Agent for Activity in Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 169.	1.7	5
31	Involvement of NF- κ B in mediating the anti-tumour effects of combretastatins in T cells. <i>Investigational New Drugs</i> , 2018, 36, 523-535.	1.2	4
32	Special Issue "Anticancer Drugs 2021". <i>Pharmaceuticals</i> , 2022, 15, 479.	1.7	2
33	Azetidin-2-ones: structures of antimitotic compounds based on the 1-(3,4,5-trimethoxyphenyl)azetidin-2-one core. <i>Acta Crystallographica Section E: Crystallographic Communications</i> , 2020, 76, 1187-1194.	0.2	1